The crosstalk between FGF21 and GH leads to weakened GH receptor signaling and IGF1 expression and is associated with growth failure in very preterm infants

Front Endocrinol (Lausanne). 2023 May 12:14:1105602. doi: 10.3389/fendo.2023.1105602. eCollection 2023.

Abstract

Background: Fibroblast growth factor 21 (FGF21) is an essential metabolic regulator that adapts to changes in nutritional status. Severe childhood undernutrition induces elevated FGF21 levels, contributing to growth hormone (GH) resistance and subsequent linear growth attenuation potentially through a direct action on chondrocytes.

Methods: In this study, we assessed expression of the components of both GH and FGF21 pathways in rare and unique human growth plates obtained from children. Moreover, we investigated the mechanistic interplay of FGF21 on GH receptor (GHR) signaling in a heterologous system.

Results: Chronic FGF21 exposure increased GH-induced GHR turnover and SOCS2 expression, leading to the inhibition of STAT5 phosphorylation and IGF-1 expression. The clinical significance of FGF21 signaling through GH receptors was tested in nutritionally driven growth failure seen in very preterm (VPT) infants right after birth. VPT infants display an immediate linear growth failure after birth followed by growth catch-up. Consistent with the in vitro model data, we show that circulating FGF21 levels were elevated during deflection in linear growth compared to catch-up growth and were inversely correlated with the length velocity and circulating IGF1 levels.

Conclusions: This study further supports a central role of FGF21 in GH resistance and linear growth failure and suggests a direct action on the growth plate.

Keywords: FGF21; GH resistance; GH signaling; growth plate; preterm infants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Fibroblast Growth Factors / metabolism
  • Growth Hormone* / metabolism
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Insulin-Like Growth Factor I*
  • Receptors, Somatotropin / genetics
  • Receptors, Somatotropin / metabolism

Substances

  • fibroblast growth factor 21
  • Growth Hormone
  • Insulin-Like Growth Factor I
  • Fibroblast Growth Factors
  • Receptors, Somatotropin
  • IGF1 protein, human

Grants and funding

JM, LG, and LD were funded by Merck Serono Grant for Growth Innovation 2014. LG is funded by the BBSRC (BB/V007246/1). US was funded by Kuopion Yliopistollinen Sairaala (US; 2017-2018), and Päivikki ja Sakari Sohlbergin Säätiö (US; 2017). LS was funded by the Swedish Research Council, Stockholm City Council, European Society for Paediatric Endocrinology, The Masonic Barnhuset Foundation in Stockholm, Sällskapet Barnavård, Märta och Gunnar V. Philipsons Stiftelse. FZ was funded by the Swedish Childhood Cancer Foundation, Åke Wibergs Stiftelse. SH is funded by the Wellcome Trust (222049/Z/20/Z) and Barts charity (MGU0552).